Skip to main content

Table 1 Comparison of demographic and clinical characteristics of cases ( E. faecium ) and controls

From: Algorithm for pre-emptive glycopeptide treatment in patients with haematologic malignancies and an Enterococcus faecium bloodstream infection

Demographics Cases (n = 33) Controls (n = 66) p-value
Male gender 18 (68.2%) 45 (54.5%) 0.184
Age, mean ± SD, years 58.0 ± 11.3 52.2 ± 9.1 0.008
Type of malignancy: a    0.378
   Leukaemia (AML, MDS, ALL) for chemotherapy 19 (57.6%) 28 (42.6%)  
   Leukemia for allogeneic stem cell transplantation 2 (6.1%) 2 (3.0%)  
   Lymphoma’s, Kahler, CLL and others undergoing autologous stem cell transplantation 6 (18.2%) 17 (25.8%)  
   Lympfhoma’s, Kahler, CLL not undergoing autologous stem cell transplantation 6 (18.2%) 19 (28.8%)  
Status of disease:    
   Remission 9 (27.3%) 11 (16.7%) 0.215
   Not in remission b 24 (72.7%) 55 (83.3%) 0.215
   Relapse 7 (21.2%) 14 (21.2%) 1.000
Reason for admission:    0.476
   Infection 4 (12.1%) 13 (19.7%)  
   Chemotherapy 21(63.6%) 34 (51.5%)  
   Stem cell transplantation c 8 (24.2%) 19 (28.8%)  
Length of hospital stay:    
   Length in days prior to positive blood culture, median (range) 21 (2–52) 13.5 (1–84) 0.007
   Length in days 1 year before admission, median (range) 43 (6–131) 24 (1–133) 0.018
Signs of organ failure: d    
   Renal (creatinine > 176 μmol/L) 2 (6.1%) 3 (4.5%) 0.746
   Hepatic (bilirubin >34 mmol/L) 2 (6.1%) 0 (0.0%) 0.109
   Lung (bilateral lung infiltrates) 4 (12.1%) 10 (15.2%) 0.769
Days of fever, median (range) d 2 (0–7) 0 (0–6) 0.001
Neutropenia:    
   Neutropenia <0.1 × 109/L e 20 (60.6%) 19 (28.8%) 0.002
   Neutropenia <0.5 × 109/L e 28 (84.8%) 28 (42.4%) <0.001
   Neutropenia <2.0 × 109/L e 29 (87.9%) 39 (59.1%) 0.004
   Duration of neutropenia <0.5 × 109/L prior to blood culture, median (range) 8.0 (0–27) 0.0 (0–26) <0.001
CRP (C-reactive protein in mg/L):    
   Levels 7 days prior to blood culture, median (range) 26 (3–263) 47 (5–347) 0.07
   Levels at time of blood culture, median (range) 188 (7–288) 108 (3–426) 0.006
   At time of blood culture CRP >125 mg/L 23 (69.7%) 24 (36.4%) 0.002
Antibiotic therapy at time of blood culture and/or 30 days before:    
   Penicillins 24 (72.7%) 40 (60.6%) 0.234
   Cotrimoxazole 12 (36.4%) 18 (27.3%) 0.353
   Quinolones 25 (75.8%) 51 (77.3%) 0.866
   Cephalosporins 6 (18.2%) 4 (6.1%) 0.079
   Carbapenems 6 (18.2%) 5 (7.6%) 0.113
   Others f 19 (57.6%) 16 (24.2%) 0.001
  1. aAML  acute myeloid leukaemia, MDS  myelodysplastic syndrome, ALL  acute lymphoblastic leukaemia, CLL  chronic lymphoblastic leukaemia. bIncluding patients partially in remission. cAllogeneic as well as autologous stem cell transplantation. dAt the day of blood culture till 7 days prior to blood culture. eAt the day of blood culture withdrawal fcolistin, tetracyclin, macrolides, aminoglycosides, metronidazole.